



Ref: BHL/ STEX 9/ 2026-27

Date: May 08, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
--	---

Sub: Press Release for the quarter and year ended March 31, 2026

Dear Sir/Madam,

Please find enclosed herewith Press Release on financial results of the Company for the quarter and year ended March 31, 2026.

Kindly take the same on record.

Thanking you.

Yours faithfully,

For and on behalf of Bajaj Healthcare Limited

Monica Tanwar
Company Secretary & Compliance Officer

Encl: As above

BAJAJ HEALTHCARE LTD

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892



Investor Release

Bajaj Healthcare Limited reports Q4 FY26 results

(12.6% Revenue Growth and 35% Rise in Profit Before Exceptional Items in FY26)

Mumbai, 08th May 2026: Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its audited financial results for the quarter and year ended 31st March 2026.

Key Financial Highlights

Particulars (Rs. Mn)	Q4 FY26	Q4 FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenue from Operations	1530.6	1,544.7	(0.9%)	6,110.3	5,426.0	12.6%
EBITDA	256.3	253.3	1.2%	1,119.5	1,018.3	9.9%
EBITDA Margin (%)	16.7%	16.4%		18.3%	18.8%	
PAT from Cont. Operations*	138.3	115.9	19.3%	545.6	429.3	27.1%
PAT Margin (Cont. Operations)*	9.0%	7.5%		8.8%	7.9%	
Profit for the period*	104.0	111.8	(7.0%)	490.1	395.0	24.1%
Profit for the period(%)*	6.8%	7.2%		7.9%	7.3%	

*Profit figures presented above are reported before exceptional items. Please refer to the explanatory statement in the MD’s commentary for further details.

Revenue Breakup

Particulars (Rs. Mn)	Q4 FY26	Q4 FY25	Y-o-Y	FY26	FY25	Y-o-Y
API (Domestic)	868.5	891.4	(2.6%)	3,195.7	3,267.1	(2.2%)
API (Exports)	385.4	407.5	(5.4%)	1,881.4	1,241.4	51.6%
Formulations	276.7	245.8	12.6%	1,033.2	917.5	12.6%

Key Highlights

- ✓ Cenobamate, a novel anti-epileptic molecule, is progressing through Phase III clinical trials as planned and is slated for launch in Q2 FY27. This milestone strengthens our presence in the CNS space, where we continue to develop innovative, high-potential molecules.
- ✓ Successfully completed the bioequivalence study for Suvorexant Tablets and will be filing the application with DCGI in the near term, marking another key milestone in drug development and clinical research.
- ✓ Filed 41 DMFs in Q4, bringing the total to 110. With these filings, the Company continues to strengthen its global regulatory presence, laying the foundation for expansion into regulated and high-value markets.



- ✓ In the current quarter, the Company completed conversion of 2,079,409 warrants into equity shares bringing additional capital amounting to INR 527 million, to strengthen the balance sheet and support growth initiatives.

Commenting on the Results, Mr. Anil Jain – Managing Director said,

“The quarter was marked by a challenging operating environment driven by continued price erosion in domestic APIs, early impacts of geopolitical disruptions in West Asia including elevated raw material prices. While revenue remained broadly stable on a YoY basis despite high teens volume growth, Profit After Tax from continuing operations before exceptional items registered healthy growth of 19% YoY, reflecting the strength of our operational discipline, cost management, and continued focus on profitability despite external headwinds.

FY26 revenue grew 12.6% YoY, driven by strong API export growth of 51.6% YoY as we witnessed healthy traction across the EU, UK, LATAM, and other regulated markets, coupled with sustained momentum in the formulations business which also recorded 12.6% YoY growth. EBITDA and overall profitability improved during the year, with PAT margin from continuing operations before exceptional items rising to 8.8% compared to 7.9% in FY25.

The formulations business continued to scale meaningfully within the overall business mix, reinforcing diversification benefits, while the CDMO business also gained traction with supplies ramping up steadily. We expect this segment to contribute more meaningfully in the coming quarters as commercial execution continues to expand. The Company also made notable progress on the regulatory and product development front during the year. We filed 41 DMFs during the quarter, taking cumulative filings to 110, further strengthening our presence in regulated markets.

The Company has reversed the income recognized in earlier financial year for transferring of technical know-how to manufacture one of the products for a party in Middle East region. The customer was not able to meet its financial commitment, due to delay in getting regulatory approvals for the project. Now due to recent ongoing regional instability in Middle East, the company has decided to cancel the arrangement and reversed the income.



Looking ahead, we remain focused on strengthening our core API business and achieving export-led growth while scaling our formulations business with an emphasis on higher-value products. We are accelerating efforts in peptides, oncology, and CNS, supported by continued investments in manufacturing, capacity expansion, and R&D-led innovation. In parallel, we are also strengthening our product pipeline to build a more diversified revenue base. With this integrated approach, Bajaj Healthcare is well positioned to deliver sustainable long-term value for stakeholders.”



About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.

Contact Details

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L99999MH1993PLC072892	Name: Ms. Prachi Ambre/ Mr. Irfan Raeen
Name: Mr. Anil Jain, MD	Email: prachi.ambre@in.mpms.mufg.com / irfan.raeen@in.mpms.mufg.com
Email: investors@bajajhealth.com	Meeting Request Link – Link

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.